|
1) 深川雅史, 平方秀樹, 秋澤忠男, 他. 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌. 2006; 39: 1435-55
|
|
|
|
|
2) Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int. 2006; Suppl(102): S3-7
|
|
|
|
|
|
3) 小野田教高, 深川雅史, 冨永芳博, 他. 副甲状腺インターベンション研究会報告: 選択的副甲状腺局注療法に関するガイドライン. 透析会誌. 2007; 40: 31-5
|
|
|
|
|
|
4) 深川雅史, 冨永芳博, 貴田岡正史, 他. 選択的PEITに関するガイドライン2000. 透析会誌. 2000; 33: 1343-5
|
|
|
|
|
|
5) Fukagawa M, Kitaoka M, Tominaga Y, et al. Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant. 2003; 18(Suppl 3): iii31-3
|
|
|
|
|
6) Nakamura M, Fuchinoue S, Teraoka S. Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism. Am J Kidney Dis. 2003; 42: 739-45
|
|
|
|
|
7) Koiwa F, Kakuta T, Tanaka R, et al. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyper-parathyroidism. Nephrol Dial Transplant. 2006; 22: 522-8
|
|
|
|
|
|
8) Tanaka M, Itoh K, Matsushita K, et al. Combination therapy of intravenous Maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism. Nephron Clin Pract. 2006; 102: c1-7
|
|
|
|
|
|
9) 冨永芳博, 貴田岡正史, 秋澤忠男, 他. わが国の腎性上皮小体(副甲状腺)機能亢進症に対する上皮小体摘出術の現況?アンケート調査結果?. 透析会誌. 2003; 36: 1361-9
|
|
|
|
|
|
10) Tanaka R, Kakuta T, Fujisaki T, et al. Long-term(3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by colour Doppler ultrasonography. Nephrol Dial Transplant. 2003; 18(Suppl 3): iii58-61
|
|
|
|
|
|
11) Barros Gueiros JE, Chammas MC, Gerhard R, et al. Percutaneous ethanol injection (PEIT) and calcitriol (PCIT) injection therapy are ineffective in treating severe secondary hyper-parathyroid-ism. Nephrol Dial. Transplant. 2004; 19: 657-63
|
|
|
|
|
|
12) Douthat WG, Orozco SE, Arteaga J, et al. Treat-ment of refractory secondary hyperparathyroidism with ethanol injection: the importance of glandular volume. Kidney Int. 2003; 63(Suppl 85): S101-4
|
|
|
|
|
|
13) Fassi J, Lambertini R, Farias P, et al. Treatment of uremic hyperparathyroidism with per-cutaneous ethanol injection. Nephron Clin Pract. 2005; 101: c53-7
|
|
|
|
|
|
14) Kitaoka M, Onoda N, Kitamura H, et al. Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial. Nephrol Dial Transplant. 2003; 18(Suppl 3): iii38-41
|
|
|
|
|
|
15) Shiizaki K, Hatamura I, Negi S, et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int. 2003; 64: 992-1003
|
|
|
|
|
|
16) Shiizaki K, Negi S, Hatamura I, et al. Biochemical and cellular effects of direct Maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol. 2005; 16: 97-108
|
|
|
|
|
|
17) Shiizaki K, Hatamura I, Negi S, et al. Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism. Kidney Int. 2006; 70: 486-95
|
|
|
|
|
|
18) Onoda N, Kashiwagi T, Nakamura T, et al. Parathyroid interventions for secondary hyper-parathyroidism in hemodialyzed patients. Ther Apher Dial. 2005; 9(Suppl 1): S11-5
|
|
|
|
|